● Recruiting

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Condition: Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Plasma Cell Leukemia · Sponsor: Shanghai Changzheng Hospital

PhaseEARLY_Phase 1

Planned participants24

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is a single-arm, open-label, exploratory dose-escalation and dose-finding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with R/R MM and PCL.RRMM and RRpPCL

This description comes directly from the study's public registry record.

Talk to the study team

Juan Du, Ph D · 15800706091 · juan_du@live.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06718270